Continuous flow production of concentrated hyperpolarized xenon gas from a dilute xenon gas mixture by buffer gas condensation

Continuous Delivery of Hyperpolarized Xenon-129 Gas Using a "Stopped-Flow" Clinical-Scale Cryogen-Free Hyperpolarizer

In 2022, the FDA approved hyperpolarized (HP) 129Xe gas as an inhalable contrast agent for functional lung imaging. For clinical imaging, HP 129Xe is usually given as a bolus inhalation. However, for preclinical applications (e.g., pulmonary imaging in small rodents), the continuous delivery of HP 129Xe is greatly desired to enable MRI scanning under conditions of physiological continuous animal breathing patterns. Moreover, HP 129Xe gas can be utilized for other applications including materials science and bioanalytical chemistry, where a continuous flow of hyperpolarized gas through an NMR sample over several minutes is also desired for sensing of 129Xe inside an NMR spectrometer. 129Xe is often hyperpolarized using continuous-flow spin-exchange optical pumping, which employs a lean (1-2%) mixture of Xe and a carrier gas (e.g., He and N2). The low Xe concentration in the produced output reduces the NMR detection sensitivity, and thus, Xe cryo-collection is typically employed to achieve near-100% pure gas-phase Xe before administration to the sample or subject. However, the need for cryo-collection undermines a key advantage of continuous-flow production, i.e., the continuous flowing in a hyperpolarizer HP 129Xe gas is trapped inside the hyperpolarizer, and the produced HP 129Xe gas is released at once when the production cycle (30-60 min) is completed. An alternative HP 129Xe production technology employs a "stopped-flow" approach, where a batch of HP gas is hyperpolarized over time and quickly released from a hyperpolarizer. Here, a clinical-scale "stopped-flow" 129Xe hyperpolarizer was employed to hyperpolarize a 1.3 L-atm batch of 50:50 Xe:N2 gas mixture inside a glass cell with an ultralong lifetime of the HP 129Xe state (T1 > 2 h). The produced HP 129Xe gas was slowly delivered into a 5 mm NMR tube via PEEK tubing under a wide range of gas flow rates: 3-180 standard cubic centimeters per minute (sccm). The polarization of the gas ejected from the hyperpolarizer was quantified using in situ low-field NMR polarimetry and additionally verified using a 0.35 T clinical MRI scanner. Continuous-flow delivery of HP 129Xe was demonstrated for up to 15 min with a gas flow rate of 45-150 sccm over a 2.5-m length of PEEK tubing, suffering only small losses in 129Xe polarization. These observations are additionally supported by 129Xe relaxation measurements inside the PEEK tubing employed for gas delivery and the 5 mm NMR tube employed for polarimetry. 129Xe polarization of 16-19% was obtained in the delivered gas, starting with an "in-polarizer" 129Xe polarization of 19%. We envision that this method can be employed for on-demand cryogen-free delivery of hyperpolarized gas using "stopped-flow" 129Xe hyperpolarizers for a broad range of applications, from preclinical imaging to biosensors, and to spectroscopy of materials surfaces.

Portable Hyperpolarized Xe-129 Apparatus with Long-Time Stable Polarization Mediated by Adaptable Rb Vapor Density

The extraordinary sensitivity of ¹²⁹Xe, hyperpolarized by spin-exchange optical pumping, is essential for magnetic resonance imaging and spectroscopy in life and materials sciences. However, fluctuations of the polarization over time still limit the reproducibility and quantification with which the interconnectivity of pore spaces can be analyzed. Here, we present a polarizer that not only produces a continuous stream of hyperpolarized ¹²⁹Xe but also maintains stable polarization levels on the order of hours, independent of gas flow rates. The polarizer features excellent magnetization production rates of about 70 mL/h and ¹²⁹Xe polarization values on the order of 40% at moderate system pressures. Key design features include a vertically oriented, large-capacity two-bodied pumping cell and a separate Rb presaturation chamber having its own temperature control, independent of the main pumping cell oven. The separate presaturation chamber allows for precise control of the Rb vapor density by restricting the Rb load and varying the temperature. The polarizer is both compact and transportable─making it easily storable─and adaptable for use in various sample environments. Time-evolved two-dimensional (2D) exchange spectra of ¹²⁹Xe absorbed in the microporous metal-organic framework CAU-1-AmMe are presented to highlight the quantitative nature of the device.

A semi-empirical model to optimize continuous-flow hyperpolarized 129Xe production under practical cryogenic-accumulation conditions

Continuous-flow spin exchange optical pumping (SEOP) with cryogenic accumulation is a powerful technique to generate multiple, large volumes of hyperpolarized (HP) 129Xe in rapid succession. It enables a range of studies, from dark matter tracking to preclinical and clinical MRI. Multiple analytical models based on first principles atomic physics and device-specific design features have been proposed for individual processes within HP 129Xe production. However, the modeling efforts have not yet integrated all the steps involved in practical, large volume HP 129Xe production process (e.g., alkali vapor generation, continuous-flow SEOP, and cryogenic accumulation). Here, we use a simplified analytical model that couples both SEOP and cryogenic accumulation, incorporating only two system-specific empirical parameters: the longitudinal relaxation time of the polycrystalline 129Xe "snow', T1snow, generated during cryogenic accumulation, and 2) the average Rb density during active, continuous-flow polarization. By fitting the model to polarization data collected from >140 L of 129Xe polarized across a range of flow and volume conditions, the estimates for Rb density and T1snow were 1.6 ± 0.1 × 1013 cm-3 and 84 ± 5 min, respectively - each notably less than expected based on previous literature. Together, these findings indicate that 1) earlier polarization predictions were hindered by miscalculated Rb densities, and 2) polarization is not optimized by maximizing SEOP efficiency with a low concentration 129Xe, but rather by using richer 129Xe-buffer gas blends that enable faster accumulation. Accordingly, modeling and experimentation revealed the optimal fraction of 129Xe, f, in the 129Xe-buffer gas blend was ~2%. Further, if coupled with modest increases in laser power, the model predicts liter volumes of HP 129Xe with polarizations exceeding 60% could be generated routinely in only tens of minutes.

XeUS: A second-generation automated open-source batch-mode clinical-scale hyperpolarizer

We present a second-generation open-source automated batch-mode ¹²⁹Xe hyperpolarizer (XeUS GEN-2), designed for clinical-scale hyperpolarized (HP) ¹²⁹Xe production via spin-exchange optical pumping (SEOP) in the regimes of high Xe density (0.66-2.5 atm partial pressure) and resonant photon flux (~170 W, Δλ = 0.154 nm FWHM), without the need for cryo-collection typically employed by continuous-flow hyperpolarizers. An Arduino micro-controller was used for hyperpolarizer operation. Processing open-source software was employed to program a custom graphical user interface (GUI), capable of remote automation. The Arduino Integrated Development Environment (IDE) was used to design a variety of customized automation sequences such as temperature ramping, NMR signal acquisition, and SEOP cell refilling for increased reliability. A polycarbonate 3D-printed oven equipped with a thermo-electric cooler/heater provides thermal stability for SEOP for both binary (Xe/N₂) and ternary (⁴He-containing) SEOP cell gas mixtures. Quantitative studies of the ¹²⁹Xe hyperpolarization process demonstrate that near-unity polarization can be achieved in a 0.5 L SEOP cell. For example, %P_Xe of 93.2 ± 2.9% is achieved at 0.66 atm Xe pressure with polarization build-up rate constant γ_SEOP = 0.040 ± 0.005 min^-1, giving a max dose equivalent ≈ 0.11 L/h 100% hyperpolarized, 100% enriched ¹²⁹Xe; %P_Xe of 72.6 ± 1.4% is achieved at 1.75 atm Xe pressure with γ_SEOP of 0.041 ± 0.001 min^-1, yielding a corresponding max dose equivalent of 0.27 L/h. Quality assurance studies on this device have demonstrated the potential to refill SEOP cells hundreds of times without significant losses in performance, with average %P_Xe = 71.7%, (standard deviation σ_P = 1.52%) and mean polarization lifetime T₁ = 90.5 min, (standard deviation σ_T = 10.3 min) over the first ~200 gas mixture refills, with sufficient performance maintained across a further ~700 refills. These findings highlight numerous technological developments and have significant translational relevance for efficient production of gaseous HP ¹²⁹Xe contrast agents for use in clinical imaging and bio-sensing techniques.

[Identification of biomarkers and new therapies for taxane-induced peripheral neuropathy]

Chemotherapy-induced peripheral neuropathy (CIPN) is a side effect frequently caused by taxanes. Because the mechanisms underlying CIPN pathogenesis remain to be fully elucidated, there is no indicator for objective diagnosis like a biomarker. In addition, treatment options for CIPN is still unsatisfactory. We have previously demonstrated that paclitaxel preferentially impair myelin-forming Schwann cells, and consequently induce dedifferentiation and demyelination of Schwann cells. Recently, in a paclitaxel CIPN model mouse, we found that an inflammatory factor is released from dedifferentiated Schwann cells in the mouse sciatic nerve into the blood, highly correlated with the on-set of mechanical hypersensitivity. On the other hand, considering our previous findings, it seems that some drugs, which supply newly formed mature Schwann cells at the sites of demyelinated lesions, may be a new beneficial therapy for taxane-induced peripheral neuropathy. In this review, we will introduce our findings about new therapeutic drug candidate for taxane-related CIPN based on this concept, and plasma biomarker to detect CIPN on-set and progression.